Clinical trial
A Phase III Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Trial of the Efficacy of Citicoline Eye Drops 2% on Visual Field Preservation in Patients With Open Angle Glaucoma
NCT05710198 is registered in ClinicalTrials.gov with Omikron Italia S.r.l. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Trial of the Efficacy of Citicoline Eye Drops 2% on Visual Field Preservation in Patients With Open Angle Glaucoma
- Lead sponsor
- Omikron Italia S.r.l.
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- December 11, 2023
- Completion date
- April 1, 2027
- Enrollment
- 1,000 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.